AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17431603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 15462235 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 40
Study 15462235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 11354304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosorba treatment
Number of subjects: 3
Study 9702141 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program to increase fruit and vegetable consumption
Number of subjects: 16
Study 9702141 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 9702141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control participants
Number of subjects: 16
Study 7746027 — intervention group
Group type: EXPERIMENTAL
Intervention: Limptar tablets (1 tablet containing 215.5 mg quinine and 167.2 mg theophylline)
Number of subjects: 12
Study 7746027 — intervention group
Group type: EXPERIMENTAL
Intervention: Limptar N tablets (1 tablet containing 165.75 mg quinine)
Number of subjects: 12
Study 7746027 — intervention group
Group type: COMPARATOR
Intervention: Chininum dihydrochloricum Buchler solution for injection (infusion of 163.3 mg quinine)
Number of subjects: 12
Study 7746027 — intervention group
Group type: COMPARATOR
Intervention: Euphyllin 0.48 (short infusion of 168.6 mg theophylline)
Number of subjects: 12
Study 30095601 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 37
Study 30095601 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/dorzolamide combination
Number of subjects: 37
Study 30095601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide monotherapy
Number of subjects: 37
Study 26708938 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 billion heat‐killed Lactobacillus paracasei MCC1849 cells (LP group)
Number of subjects: 42
Study 26708938 — intervention group
Group type: COMPARATOR
Intervention: Placebo jelly without lactobacilli (placebo group)
Number of subjects: 42
Study 26514192 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 0.9 mg/kg
Number of subjects: 30
Study 26514192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.25 mg/kg
Number of subjects: 30
Study 23102686 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 59
Study 23102686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 20860592 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with low-level laser therapy
Number of subjects: 24
Study 20860592 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment alone (Control)
Number of subjects: 24
Study 18082233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 96
Study 18082233 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 96
Study 16649887 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8-week outpatient exercise program)
Number of subjects: 84
Study 16649887 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 84
Study 14569829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position during transcranial Doppler (TCD) examination
Number of subjects: 34
Study 14569829 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position during transcranial Doppler (TCD) examination
Number of subjects: 34
Study 14569829 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both positions (sitting and supine)
Number of subjects: 34
Study 10858678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough test
Number of subjects: 44
Study 10858678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap test
Number of subjects: 44
Study 10858678 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenberg test
Number of subjects: 44
Study 10858678 — intervention group
Group type: EXPERIMENTAL
Intervention: Perthes' test
Number of subjects: 44
Study 10858678 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held Doppler assessment
Number of subjects: 44
Study 9351762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet on triple-marker screening
Number of subjects: 197
Study 9351762 — intervention group
Group type: COMPARATOR
Intervention: Control pamphlet on daily activities during pregnancy
Number of subjects: 197
Study 8458315 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy supplement (3.31 MJ daily) for 3 months
Number of subjects: 0
Study 8458315 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole at the beginning of supplementation
Number of subjects: 0
Study 8458315 — intervention group
Group type: COMPARATOR
Intervention: Standard health service care
Number of subjects: 0
Study 8458315 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy supplement
Number of subjects: 0
Study 3739582 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 30
Study 3739582 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 30
Study 30227884 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) group
Number of subjects: 10
Study 30227884 — intervention group
Group type: COMPARATOR
Intervention: Conventional Exercise (CON) group
Number of subjects: 10
Study 26572887 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanogram with 10% of the standard dose of ionizing radiation
Number of subjects: 10
Study 26572887 — intervention group
Group type: COMPARATOR
Intervention: CT scanogram with 90% of the standard dose of ionizing radiation
Number of subjects: 10
Study 26572887 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of native and repaired femurs using both doses
Number of subjects: 10
Study 24807320 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative depression management (n=102)
Number of subjects: 205
Study 24807320 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=103)
Number of subjects: 205
Study 22436082 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care program (N = 93)
Number of subjects: 185
Study 22436082 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N = 92)
Number of subjects: 185
Study 20439201 — intervention group
Group type: EXPERIMENTAL
Intervention: Heiney‐Adams Recruitment Framework (H‐ARF)
Number of subjects: 0
Study 20439201 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Insurance Portability and Accountability Act waivers
Number of subjects: 0
Study 18662214 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary fall-prevention program
Number of subjects: 333
Study 18662214 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 333
Study 16270700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat) treatment applied twice a year at six-month intervals in school settings among 854 adolescents.
Number of subjects: 854
Study 16270700 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised school-based fluoride mouth rinse (FMR) on the first three and last three school days during the school term (12 rinses/year) among 788 adolescents.
Number of subjects: 854
Study 16270700 — intervention group
Group type: COMPARATOR
Intervention: Cessation of fluoride mouth rinse (FMR) for 3 years in a group of 60 adolescents with low caries prevalence.
Number of subjects: 854
Study 11877694 — intervention group
Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (CDU) scan
Number of subjects: 83
Study 11877694 — intervention group
Group type: COMPARATOR
Intervention: Computed tomographic (CT) scan
Number of subjects: 83
Study 11877694 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler scan waveform pattern
Number of subjects: 83
Study 11877694 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous seal of T2ELs
Number of subjects: 83
Study 11877694 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of endoleaks
Number of subjects: 83
Study 11877694 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate of endoleaks
Number of subjects: 83
Study 10412990 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysplastic hips (intervention group)
Number of subjects: 66
Study 10412990 — intervention group
Group type: COMPARATOR
Intervention: Normal hips (control group)
Number of subjects: 66
Study 7589414 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational multiple family groups (MFGs)
Number of subjects: 0
Study 7589414 — intervention group
Group type: COMPARATOR
Intervention: Single-family format
Number of subjects: 0
Study 7589414 — intervention group
Group type: COMPARATOR
Intervention: MFGs without psychoeducation
Number of subjects: 0
Study 2133939 — intervention group
Group type: EXPERIMENTAL
Intervention: Scavenged group (nitrous oxide with scavenging system)
Number of subjects: 20
Study 2133939 — intervention group
Group type: COMPARATOR
Intervention: Nonscavenged control (nitrous oxide without scavenging system)
Number of subjects: 20
Study 7453037 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% bromhexine eye drops
Number of subjects: 24
Study 7453037 — intervention group
Group type: COMPARATOR
Intervention: 0.5% methyl cellulose eye drops
Number of subjects: 24
Study 31335201 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump (CSII)
Number of subjects: 96
Study 31335201 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 96
Study 31335201 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 96
Study 31335201 — intervention group
Group type: COMPARATOR
Intervention: Conventional self-monitoring of blood glucose (SMBG)
Number of subjects: 96
Study 28934525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap condition (45-minute nap at 1300 h)
Number of subjects: 19
Study 28934525 — intervention group
Group type: COMPARATOR
Intervention: No-Nap condition
Number of subjects: 19
Study 27126957 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group consumed fermented milk with Bifidobacterium lactis HN019 (80 mL daily, 2.72 × 10^10 CFU) for 45 days
Number of subjects: 51
Study 27126957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51
Study 27126957 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group consumed fermented milk with Bifidobacterium lactis HN019
Number of subjects: 51
Study 24483160 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated glycemic control with adaptive meal-priming boluses
Number of subjects: 24
Study 24483160 — intervention group
Group type: COMPARATOR
Intervention: Automated glycemic control without adaptive meal-priming boluses
Number of subjects: 24
Study 22520791 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure and self-titration of antihypertensive medication
Number of subjects: 23
Study 19643310 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 112
Study 19643310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 17166220 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 4782
Study 17166220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4782
Study 16279581 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet data capture
Number of subjects: 0
Study 16279581 — intervention group
Group type: COMPARATOR
Intervention: Paper-based data recording
Number of subjects: 0
Study 11926889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole, 0.5 mg 3 times per day with levodopa placebo (n = 42)
Number of subjects: 82
Study 11926889 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa/levodopa, 25/100 mg 3 times per day with pramipexole placebo (n = 40)
Number of subjects: 82
Study 10347342 — intervention group
Group type: EXPERIMENTAL
Intervention: Later intra-aortic balloon pump (IABP) deflation
Number of subjects: 43
Study 10347342 — intervention group
Group type: COMPARATOR
Intervention: Conventional IABP timing
Number of subjects: 43
Study 7753739 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 7753739 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and heparin (adjunctive drugs)
Number of subjects: 0
Study 7753739 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers and angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 7753739 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 0
Study 7753739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0
Study 2190864 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 0
Study 2190864 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg four times daily
Number of subjects: 0
Study 7415650 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 units of subcutaneous heparin twice a day for a fortnight
Number of subjects: 150
Study 7415650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 150
Study 7415650 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized group
Number of subjects: 150
Study 29615077 — intervention group
Group type: EXPERIMENTAL
Intervention: SGI-110 (guadecitabine) combined with gemcitabine and cisplatin (GC) chemotherapy
Number of subjects: 56
Study 29615077 — intervention group
Group type: COMPARATOR
Intervention: GC chemotherapy (cisplatin 70 mg/m2, IV infusion, day 8; gemcitabine 1000 mg/m2, IV infusion, days 8 and 15)
Number of subjects: 56
Study 26945890 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG alone (247 patients)
Number of subjects: 487
Study 26945890 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + isoniazid (240 patients)
Number of subjects: 487
Study 26945890 — intervention group
Group type: COMPARATOR
Intervention: BCG alone and BCG + isoniazid
Number of subjects: 487
Study 23962460 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (temperature 31 °C‐32 °C)
Number of subjects: 140
Study 23962460 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB (temperature >36 °C)
Number of subjects: 140
Study 23962460 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB
Number of subjects: 140
Study 23962460 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB
Number of subjects: 140
Study 22686495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxycodone (0, 14 & 28 mg)
Number of subjects: 8
Study 22686495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 20556471 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐monthly laser treatments with a StarLux 1,540‐nm fractional handpiece
Number of subjects: 10
Study 20556471 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 10
Study 18793361 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-mechanical root canal preparation
Number of subjects: 40
Study 18793361 — intervention group
Group type: COMPARATOR
Intervention: Primary infections
Number of subjects: 40
Study 15640294 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Respiratory Illness and Flu Scale (CARIFS) data from a randomized controlled trial cohort
Number of subjects: 0
Study 12766099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oolong tea (1,500 ml) for 30 days
Number of subjects: 20
Study 12766099 — intervention group
Group type: COMPARATOR
Intervention: Water (control) for 30 days
Number of subjects: 20
Study 10758942 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine combined with fenfluramine
Number of subjects: 0
Study 10758942 — intervention group
Group type: COMPARATOR
Intervention: Phentermine alone
Number of subjects: 0
Study 8930172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA)
Number of subjects: 37
Study 8930172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) 30 mg/kg
Number of subjects: 37
Study 8930172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) 100 mg/kg
Number of subjects: 37
Study 8930172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) 15-50 mg/kg (second infusions)
Number of subjects: 37
Study 8930172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1732896 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg)
Number of subjects: 44
Study 1732896 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 44
Study 6423317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol (1 mg/actuation)
Number of subjects: 25
Study 6423317 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate via Spinhaler (20 mg)
Number of subjects: 25
Study 30282077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (SH) treatment
Number of subjects: 0
Study 30282077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 29590544 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of CAPOX (capecitabine and oxaliplatin)
Number of subjects: 12834
Study 29590544 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 12834
Study 29590544 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of therapy (combined regimens)
Number of subjects: 12834
Study 29590544 — intervention group
Group type: COMPARATOR
Intervention: 6 months of therapy (combined regimens)
Number of subjects: 12834
Study 26509371 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibram FiveFingers™ group
Number of subjects: 37
Study 26509371 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional running shoes)
Number of subjects: 37
Study 1449019 — intervention group
Group type: EXPERIMENTAL
Intervention: Urso plus colchicine (1 mg/day)
Number of subjects: 22
Study 1449019 — intervention group
Group type: COMPARATOR
Intervention: Urso plus placebo
Number of subjects: 22
Study 1449019 — intervention group
Group type: EXPERIMENTAL
Intervention: Urso alone (10-12 mg/kg) for 12 months
Number of subjects: 22
Study 22695257 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-based cognitive training (AT) plus social cognition training (SCT)
Number of subjects: 22
Study 22695257 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition of non-specific computer games (CG)
Number of subjects: 22
Study 20394080 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted analysis
Number of subjects: 0
Study 20394080 — intervention group
Group type: EXPERIMENTAL
Intervention: Unweighted analysis
Number of subjects: 0
Study 20394080 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed procedure
Number of subjects: 0
Study 18713809 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 579
Study 18713809 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (6 sessions)
Number of subjects: 579
Study 18713809 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexander technique (6 lessons)
Number of subjects: 579
Study 18713809 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexander technique (24 lessons)
Number of subjects: 579
Study 18713809 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prescription
Number of subjects: 579
Study 16326671 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.25 to 0.5 mg.kg(‐1))
Number of subjects: 27
Study 16326671 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (1.0 mg.kg(‐1))
Number of subjects: 27
Study 16326671 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.5 mg.kg(‐1))
Number of subjects: 27
Study 16326671 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 27
Study 16326671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both esmolol and landiolol
Number of subjects: 27
Study 12432320 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (ET) performed on postburn day (PBD) 4
Number of subjects: 44
Study 12432320 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CON) with tracheostomy performed on PBD 14 if necessary
Number of subjects: 44
Study 10521736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (20 mg every 4‐6 hours)
Number of subjects: 74
Study 10521736 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 74
Study 8890875 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical interventions
Number of subjects: 152
Study 1683333 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine (3 x 75 mg)
Number of subjects: 0
Study 1683333 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (3 x 4 mg)
Number of subjects: 0
Study 6845096 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 100
Study 6845096 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 100
Study 31595970 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment plus imaging (EUS and [18 F]FDG PET/CT)
Number of subjects: 183
Study 31595970 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical assessment
Number of subjects: 183
Study 31595970 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging group (EUS and PET/CT)
Number of subjects: 183
Study 31595970 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 183
Study 30373785 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care supplemented with an electronic patient-reported outcome measure (ePROM) intervention
Number of subjects: 66
Study 30373785 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 27794080 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeO2 (variable oxygen flow)
Number of subjects: 16
Study 27794080 — intervention group
Group type: COMPARATOR
Intervention: Oxygen at 2 L/min
Number of subjects: 16
Study 27794080 — intervention group
Group type: COMPARATOR
Intervention: Air at 2 L/min
Number of subjects: 16
Study 24604881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild depressive symptoms (PHQ-9 score 5-9)
Number of subjects: 1418
Study 24604881 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe depressive symptoms (PHQ-9 score ≥10)
Number of subjects: 1418